blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3827815

EP3827815 - TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS [Right-click to bookmark this link]
StatusThe patent has been granted
Status updated on  04.08.2023
Database last updated on 15.06.2024
FormerGrant of patent is intended
Status updated on  15.06.2023
FormerRequest for examination was made
Status updated on  03.12.2021
FormerThe application has been published
Status updated on  30.04.2021
Most recent event   Tooltip24.05.2024Lapse of the patent in a contracting state
New state(s): IT, LU, LV, PL		published on 26.06.2024 [2024/26]
Applicant(s)For all designated states
PTC Therapeutics, Inc.
500 Warren Corporate Center Drive
Warren, NJ 07059 / US
[2024/23]
Former [2021/22]For all designated states
PTC Therapeutics, Inc.
100 Corporate Court, Middlesex Business Center
South Plainfield, NJ 07080 / US
Inventor(s)01 / MILLER, Guy. M
c/o PTC Therapeutics, Inc.
100 Corporate Court
Middlesex Business Center
South Plainfield, NJ New Jersey 07080 / US
02 / KHEIFETS, Viktoria
c/o PTC Therapeutics, Inc.
100 Corporate Court
Middlesex Business Center
South Plainfield, New Jersey 07080 / US
 [2021/22]
Representative(s)J A Kemp LLP
80 Turnmill Street
London EC1M 5QU / GB
[2023/36]
Former [2021/22]J A Kemp LLP
14 South Square
Gray's Inn
London WC1R 5JJ / GB
Application number, filing date20216131.108.09.2009
[2021/22]
Priority number, dateUS20080191696P10.09.2008         Original published format: US 191696 P
[2021/22]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3827815
Date:02.06.2021
Language:EN
[2021/22]
Type: B1 Patent specification 
No.:EP3827815
Date:06.09.2023
Language:EN
[2023/36]
Search report(s)(Supplementary) European search report - dispatched on:EP03.05.2021
ClassificationIPC:A61K31/05, A61K31/122, A61P25/00, A61P25/14, A61P25/18, A61P25/28, A23L33/10, C07C39/08
[2021/22]
CPC:
A61K31/122 (EP,US); A23L33/10 (EP,US); A23L33/40 (US);
A61K31/05 (EP,US); A61P25/00 (EP); A61P25/14 (EP);
A61P25/18 (EP); A61P25/28 (EP); C07C39/08 (EP,US);
C07C50/02 (EP,US); C07C50/06 (US); A23V2002/00 (US);
C07C2601/16 (EP) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   SM,   TR [2022/01]
Former [2021/22]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  SE,  SI,  SK,  SM,  TR 
TitleGerman:BEHANDLUNG VON PERVASIVEN ENTWICKLUNGSSTÖRUNGEN MIT REDOX-AKTIVEN THERAPEUTIKA[2021/22]
English:TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS[2021/22]
French:TRAITEMENT DES TROUBLES PERVASIFS DU DÉVELOPPEMENT AVEC DES AGENTS THÉRAPEUTIQUES À ACTIVITÉ REDOX[2021/22]
Examination procedure01.12.2021Amendment by applicant (claims and/or description)
01.12.2021Examination requested  [2022/01]
01.12.2021Date on which the examining division has become responsible
16.06.2023Communication of intention to grant the patent
27.07.2023Fee for grant paid
27.07.2023Fee for publishing/printing paid
27.07.2023Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP09792325.4  / EP2344142
Fees paidRenewal fee
21.12.2020Renewal fee patent year 03
21.12.2020Renewal fee patent year 04
21.12.2020Renewal fee patent year 05
21.12.2020Renewal fee patent year 06
21.12.2020Renewal fee patent year 07
21.12.2020Renewal fee patent year 08
21.12.2020Renewal fee patent year 09
21.12.2020Renewal fee patent year 10
21.12.2020Renewal fee patent year 11
21.12.2020Renewal fee patent year 12
21.09.2021Renewal fee patent year 13
21.09.2022Renewal fee patent year 14
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT06.09.2023
CZ06.09.2023
EE06.09.2023
ES06.09.2023
FI06.09.2023
HR06.09.2023
IT06.09.2023
PL06.09.2023
RO06.09.2023
SE06.09.2023
SK06.09.2023
SM06.09.2023
LU08.09.2023
LV08.09.2023
NO06.12.2023
GR07.12.2023
IS06.01.2024
PT08.01.2024
[2024/26]
Former [2024/23]AT06.09.2023
CZ06.09.2023
EE06.09.2023
ES06.09.2023
FI06.09.2023
HR06.09.2023
RO06.09.2023
SE06.09.2023
SK06.09.2023
SM06.09.2023
NO06.12.2023
GR07.12.2023
IS06.01.2024
PT08.01.2024
Former [2024/20]FI06.09.2023
HR06.09.2023
SE06.09.2023
SM06.09.2023
NO06.12.2023
GR07.12.2023
IS06.01.2024
Former [2024/10]FI06.09.2023
HR06.09.2023
SE06.09.2023
NO06.12.2023
GR07.12.2023
Former [2024/09]FI06.09.2023
SE06.09.2023
NO06.12.2023
GR07.12.2023
Former [2024/08]NO06.12.2023
GR07.12.2023
Documents cited:Search[A]WO2005115478  (UNIV CALIFORNIA [US], et al) [A] 1-12 * paragraph [0054] *;
 [AD]US2006281809  (MILLER GUY M [US], et al) [AD] 1-12 * paragraphs [0080] , [0084] , [0108] , [0109] , [0111] , [0166] - [0169] *;
 [ID]US2007072943  (MILLER GUY M [US], et al) [ID] 1-12 * paragraphs [0016] , [0110] , [0111] *;
 [A]  - ANTALIS CARYL J ET AL, "High dietary alpha tocopherol improves attention deficit/hyperactivity (ADHD)-like behavior in juvenile spontaneously hypertensive rats (SHR)", FASEB JOURNAL, FED. OF AMERICAN SOC. FOR EXPERIMENTAL BIOLOGY, BETHESDA, MD, US, (20060307), vol. 20, no. 5, ISSN 0892-6638, page A1003, XP009125315 [A] 1-12 * the whole document *
 [A]  - CHAUHAN A ET AL, "Oxidative stress in autism", PATHOPHYSIOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 13, no. 3, ISSN 0928-4680, (20060801), pages 171 - 181, (20060801), XP025137500 [A] 1-12 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.pathophys.2006.05.007
by applicantUS3406188
 US4310465
 US2005203066
 US2006281809
 US2007072943
 US2007225261
    - LORD C et al., "Autism spectrum disorders", Neuron, (20000000), vol. 28, no. 2, pages 355 - 63, XP055422327
    - GOLDSTEIN S et al., "The Comorbidity of Pervasive Developmental Disorder and Attention Deficit Hyperactivity Disorder: Results of a Retrospective Chart Review", Journal of Autism and Developmental Disorders, (20040000), vol. 34, no. 3, pages 329 - 339
    - HATTORI J et al., Are Pervasive Developmental Disorders and Attention Deficit/Hyperactivity Disorder Distinct Disorders?
    - VOLKMAR F et al., "Autism in infancy and early childhood", Annu Rev Psychol, (20050000), vol. 56, pages 315 - 36
    - SIGMAN M et al., "Early detection of core deficits in autism", Merit Retard Dev Disabil Res Rev, (20040000), vol. 10, no. 4, pages 221 - 33
    - NOENS I et al., "The ComFor: an instrument for the indication of augmentative communication in people with autism and intellectual disability", J Intellect Disabil Res, (20060000), vol. 50, no. 9, doi:10.1111/j.1365-2788.2006.00807.x, pages 621 - 32, XP008095447

DOI:   http://dx.doi.org/10.1111/j.1365-2788.2006.00807.x
    - COLEMAN M. et al., "Autism and Lactic Acidosis", J. Autism Dev Disord., (19850000), vol. 15, pages 1 - 8
    - LASZLO et al., "Serum serotonin, lactate and pyruvate levels in infantile autistic children", Clin. Chim. Acta, (19940000), vol. 229, doi:10.1016/0009-8981(94)90243-7, pages 205 - 207, XP025201154

DOI:   http://dx.doi.org/10.1016/0009-8981(94)90243-7
    - CHUGANI et al., "Evidence of altered energy metabolism in autistic children", Progr. NeuropsychopharmacolBiolPsychiat., (19990000), vol. 23, pages 635 - 641
    - OLIVEIRA, G., Developmental Medicine & Child Neurology, (20050000), vol. 47, pages 185 - 189
    - FILIPEK, PA et al., Journal of Autism and Developmental Disorders, (20040000), vol. 34, pages 615 - 623
    - ROSSIGNOL, D.A. et al., Am J. Biochem. & Biotech, vol. 4, no. 2, pages 208 - 217
    - MYERS SM et al., "Management of children with autism spectrum disorders", Pediatrics, (20070000), vol. 120, no. 5, doi:10.1542/peds.2007-2362, pages 1162 - 82, XP055287507

DOI:   http://dx.doi.org/10.1542/peds.2007-2362
    - ANGLEY M et al., "Children and autism—part 1— recognition and pharmacological management", Aus.t Fam. Physician, (20070000), vol. 36, no. 9, pages 741 - 4
    - ROGERS SJ et al., "Evidence-based comprehensive treatments for early autism", J Clin. Child Adolesc. Psychol., (20080000), vol. 37, no. 1, pages 8 - 38
    - OSWALD DP et al., "Medication Use Among Children with Autism Spectrum Disorders", J Child Adolesc Psychopharmacol, (20070000), vol. 17, no. 3, pages 348 - 55
    - COLEMAN, M. et al., Journal of Autism and Developmental Disorders, (19850000), vol. 15, pages 1 - 8
    - FILIPEK, PA et al., J, Autism Dev. Diosrd., (20040000), vol. 34, pages 615 - 23
    - STEGHENS, J. P. et al., Free Radic Biol Med, (20010000), vol. 31, page 242
    - PILZ, J, Chromatogr B Biomed Sci appl, (20000000), vol. 742, page 315
    - KORIZIS, K. N. et al., Biomed Chromatogr, (20010000), vol. 15, page 287
    - K FUKANAGA et al., Biomed Chromatogr, (19980000), vol. 12, page 300
    - LEE, Diffusion-Controlled Matrix Systems, pages 155 - 198
    - RONLANGER, Erodible Systems, pages 199 - 224
    - Methods in Cell Biology, Academic Press, (19760000), vol. XIV, page 33
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.